Results 21 to 30 of about 53,685 (285)

Levodopa in the Treatment of Parkinson's Disease: Current Status and New Developments

Journal of Parkinson’s Disease, 2013
Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). Oral levodopa has been widely used for over 40 years, often in combination with a dopa-decarboxylase inhibitor (DDCI ...
David Salat, Eduardo Tolosa
doaj   +1 more source

Plasma 3-O-Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report. [PDF]

Mov Disord Clin Pract
Movement Disorders Clinical Practice, EarlyView.
Okusa S, Okada K, Nihei Y, Sakai R, Akiyoshi T, Nukariya T, Nakahara J, Ohtani H, Seki M.   +8 more
europepmc   +2 more sources

Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa

ADMET and DMPK, 2022
Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration.
Emelia Priscilla Imbeah, Ofosua Adi-Dako, Benoit N’guessan, Kennedy Kwami Edem Kukuia, Benedicta Obenewaa Dankyi, Ismaila Adams, Ebenezer Ofori-Attah, Regina Appiah-Opong, Seth Kwabena Amponsah   +8 more
doaj   +1 more source

Levodopa-equivalent doses during follow-up.

, 2018
Levodopa-equivalent doses during follow-up.
Young H. Sohn (116741), Yoonju Lee (3509252), Seok Jong Chung (497755), Jae Jung Lee (2966892), Jungsu S. Oh (2833025), Su Jin Chung (2966886), Hyojeong Moon (5770775), Phil Hyu Lee (116745), Jae Seung Kim (469176)   +8 more
core   +1 more source

Levodopa-responsive Holmes head titubation caused by midbrain cavernoma hemorrhage

, 2021
Levodopa-responsive Holmes head titubation caused by midbrain cavernoma ...
SM Slootjes (14479878), T Lejeune (13743994), T Duprez (13346010), TM Lawson (14479881), A Peeters (9174206)   +4 more
core  

Plasma hsa-mir-19b is a potential LevoDopa therapy marker [PDF]

, 2021
Parkinson's disease (PD) is the second most common neurodegenerative disorder among the elderly, the diagnostic and prognostic of which is based mostly on clinical signs.
Rosca, Cecilia, Ioan Ovidiu Sirbu, Ruxandra Julia Vorovenci, Bejinar, Cristina, Chis, Aimee Rodica, Vorovenci, Ruxandra Julia, Cecilia Rosca, Dijmarescu, Cristina, Catalin Marian, Marian, Catalin, Mihaela Simu, Dolga, Amalia; id_orcid, Cristina Dijmarescu, Moatar, Alexandra Ioana, Simu, Mihaela, Alexandra Ioana Moatar, Inge Krabbendam, Krabbendam, Inge, Amalia Dolga, Aimee Rodica Chis, Cristina Bejinar, Sirbu, Ioan Ovidiu   +21 more
core   +1 more source

A regression analytical model of serum levodopa metabolic profile in Parkinson's disease

Heliyon
Although levodopa and its metabolites in blood have been investigated in parkinsonian disorders for biomarkers, medication effects of levodopa-associated drugs remain unclear. In this study, we investigated levodopa associated metabolites to characterize
Akiko Chukyo, Osamu Komori, Motoki Fujimaki, Naoko Kaga, Hikari Taka, Yuanzhe Li, Shin-Ichi Ueno, Haruka Takeshige-Amano, Manabu Funayama, Tomohiro Ishimaru, Hirofumi Teranishi, Taku Hatano, Kei-Ichi Ishikawa, Yutaka Oji, Taiji Tsunemi, Yuta Ishiguro, Kensuke Daida, Yoko Imamichi, Noriko Nishikawa, Takashi Ueno, Yoshiki Miura, Shogo Ohuchi, Tetsushi Kataura, Nobutaka Hattori, Shinji Saiki   +24 more
doaj   +1 more source

Levodopa-equivalent dose and follow-up duration between the two groups.

, 2016
HNM-PD (closed circle) received higher levodopa-equivalent dose than LNM-PD (open circle) at similar follow-up duration. However, group (HNM-PD, solid line/LNM-PD, dotted line) and follow-up duration interaction was non-significant for levodopa ...
Jee Hyun Ham (2966889), Young H. Sohn (116741), Jae Jung Lee (2966892), Su Jin Chung (2966886), Phil Hyu Lee (116745), Byoung Seok Ye (469171)   +5 more
core   +1 more source

Gout and Levodopa: An unknown adverse effect?

, 2021
International audienceAbstract We report the case of a 77‐year‐old man with Parkinson's disease (PD) who experimented for the first time gout crisis after the initiation of levodopa.
Khouri, Charles, Athan Baillet, Elena Moro, Baillet, Athan, Romain Gastaldi, Charles Khouri, Moro, Elena, Gastaldi, Romain, Allenet, Benoit, Laura Quarteroni, Benoit Allenet, Quarteroni, Laura   +11 more
core   +1 more source

Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson’s disease

Therapeutic Advances in Chronic Disease, 2019
Background: Inhaled levodopa may quickly resolve off periods in Parkinson’s disease. Our aim was to determine the pharmacokinetics and tolerability of a new levodopa dry-powder inhaler.
Marianne Luinstra, Wijnand Rutgers, Teus van Laar, Floris Grasmeijer, Anja Begeman, Valmira Isufi, Luc Steenhuis, Paul Hagedoorn, Anne de Boer, Henderik W. Frijlink   +9 more
doaj   +1 more source